BYSI - BeyondSpring regains Nasdaq compliance on minimum bid price
- Clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, BeyondSpring ( NASDAQ: BYSI ) received a written notification from Nasdaq that the company has regained compliance with the minimum bid price requirement.
- Nasdaq has determined that for the 10 consecutive business days from December 14, 2022 to December 28, 2022, the closing bid price of the company’s shares had been at $1.00 per share or greater.
- Accordingly, the Company has regained compliance with the Nasdaq Listing Rule 5550(a)(2) and the bid price deficiency matter as previously disclosed is now
For further details see:
BeyondSpring regains Nasdaq compliance on minimum bid price